搜尋
Immix Biopharma Inc
IMMX添加自選
10.340USD
+0.510+5.19%
收盤 07/02, 13:00（美東）報價延遲15分鐘
721.63M總市值
虧損本益比TTM
關於 Immix Biopharma Inc 公司
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Immix Biopharma Inc簡介
公司代碼IMMX
公司名稱Immix Biopharma Inc
上市日期Dec 16, 2021
CEORachman (Ilya)
員工數量18
證券類型Ordinary Share
年結日Dec 16
公司地址11400 West Olympic Blvd.
城市LOS ANGELES
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編90064
電話18889581084
網址https://immixbio.com/
公司代碼IMMX
上市日期Dec 16, 2021
CEORachman (Ilya)
Immix Biopharma Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
常見問題
Immix Biopharma Inc的前五大股東是誰？
Immix Biopharma Inc的前五大股東如下：Mr. Jason Hsu, Ph.D.
有多少機構持有Immix Biopharma Inc(IMMX)的股份？
截至2026Q1，共有105家機構持有Immix Biopharma Inc的股份，合計持有的股份價值約為24.89M，占公司總股份的45.75% 。與2025Q4相比，機構持股有所增加，增幅為18028804.00。